ODPRN Unit Leads

Tara Gomes is co-Principal Investigator of the ODPRN.

Headshot Gomes

Dr. Tara Gomes is an epidemiologist and Principal Investigator of the Ontario Drug Policy Research Network (ODPRN), a provincial network of researchers with expertise in pharmaceutical utilization, outcomes and policy who rapidly conduct research for drug decision-makers in Ontario and across Canada. She is also a Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital and the Institute for Clinical Evaluative Sciences and an assistant professor at the University of Toronto. Her research is focused on pharmacoepidemiology, drug safety and drug policy research leveraging large, administrative databases, and she has published over 125 peer-reviewed articles and over 50 policy reports in this area. Dr. Gomes has worked closely with the Ontario Ministry of Health and Long-Term Care and the Canadian Network for Observational Drug Effect Studies (CNODES) to develop evidence to inform policies related to opioid use and abuse in Ontario and more broadly across Canada. She has also served as an expert for the US Food and Drug Administration and the US Department of Transportation in discussions related to opioid policies and regulations. In 2014, the ODPRN was awarded the Institute for Public Administration of Canada’s Bronze Public Sector Leadership Award in Health and Education. See Current Publications from PubMed.

Muhammad Mamdani is co-Principal Investigator of the ODPRN.

Muhammad Mamdani

Dr. Muhammad Mamdani is the Director of the Applied Health Research Centre (AHRC), the Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto. He is also Associate Professor in the Leslie Dan Faculty of Pharmacy and in the Dept of Health Policy, Management and Evaluation of the Faculty of Medicine, where he supervises graduate students and an adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES). Prior to joining the Li Ka Shing Knowledge Institute and St. Michael’s Hospital, Dr. Mamdani was a Director of Outcomes Research at Pfizer Global Pharmaceuticals in New York. Dr. Mamdani’s research interests include pharmacoepidemiology, pharmacoeconomics, and drug policy. He has published over 200 research studies in peer-reviewed medical journals. Dr. Mamdani obtained a Doctor of Pharmacy degree (PharmD) from the University of Michigan (Ann Arbor) in 1995 and subsequently completed a fellowship in pharmacoeconomics and outcomes research at the Detroit Medical Center in 1997. During his fellowship, Dr. Mamdani obtained a Master of Arts degree in Economics from Wayne State University in Detroit, Michigan. He then completed a Master of Public Health degree from Harvard University in 1998 with a concentration in quantitative methods, focusing on biostatistics and epidemiological principles. See Current Publications in PubMed.

David Juurlink is co-Principal Investigator of the ODPRN.

David Juurlink

Dr. David Juurlink is the Eaton Scholar and Professor of Medicine and Pediatrics at the University of Toronto, a Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES), and Head of the Division of Clinical Pharmacology and Toxicology at the University of Toronto. He is a staff internist at Sunnybrook Hospital and a consulting medical toxicologist at the Ontario Poison Centre at the Hospital for Sick Children. In addition to his clinical work, he maintains an active research program in drug safety, the consequences of drug interactions in clinical practice, and the epidemiology of self-harm and suicide. See Current Publications in PubMed.




Amit Garg is lead of the ODPRN Student Training Program.

Amit Garg

Dr. Amit Garg is a Professor of Medicine, Epidemiology & Biostatistics at the University of Western Ontario. He practices nephrology at the London Health Sciences Centre and cares for patients with chronic kidney disease, acute kidney injury and individuals wishing to donate a kidney to a loved one. Dr. Garg conducts clinical and health services research to improve health outcomes for patients with kidney diseases including those receiving dialysis or a kidney transplant. He also aims to improve the efficiency by which renal care is delivered. He currently holds a Clinician Scientist Award from the Canadian Institutes of Health Research. He is the current Director of the London Kidney Clinical Research Unit and Scientific Director of the Institute for Clinical Evaluative Sciences @ Western Facility. See Current Publications in PubMed.

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.